
## Frankie Ann Holmes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611865/publications.pdf Version: 2024-02-01



| #  | Article  | IF              | CITATIONS    |
|----|--|-----------------|--------------|
| 1  | Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. Cancer Research, 2022, 82, P2-13-21-P2-13-21.                      | 0.9             | 1            |
| 2  | Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated<br>Cytotoxicity in HER2-expressing Breast Cancer. Clinical Cancer Research, 2021, 27, 807-818.  | 7.0             | 34           |
| 3  | Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. Cancer Research, 2021, 81, PD3-03-PD3-03.  | 0.9             | 2            |
| 4  | A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide<br>in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research, 2020, 26,<br>6149-6157.   | 7.0             | 29           |
| 5  | Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. Current Problems in Cancer Case Reports, 2020, 2, 100033.   | 0.1             | 1            |
| 6  | Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. Npj Breast Cancer, 2019, 5, 36.   | 5.2             | 9            |
| 7  | Fiveâ€year results of a phase <scp>II</scp> trial of preoperative 5â€fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine ( <scp>wTX</scp> ) (with trastuzumab in) Tj ETQq1 1 cancer. Cancer Medicine. 2018. 7. 2288-2298.                             | 0.784314<br>2.8 | rgBT /Overlo |
| 8  | Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer Journal of Clinical Oncology, 2016, 34, TPS10144-TPS10144.   | 1.6             | 0            |
| 9  | Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase<br>III Adjuvant Trial of Capecitabine. Clinical Cancer Research, 2015, 21, 4305-4311.  | 7.0             | 51           |
| 10 | HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified<br>residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or<br>both (HL) Journal of Clinical Oncology, 2015, 33, 621-621.          | 1.6             | 0            |
| 11 | Scalp cooling alopecia prevention trial (SCALP) Journal of Clinical Oncology, 2014, 32, TPS9660-TPS9660.   | 1.6             | 0            |
| 12 | Evidence of <i>PIK3CA</i> and <i>TP53</i> co-mutation in breast cancer identification on<br>next-generation sequencing (NGS) of <i>ERBB2</i> ( <i>HER2</i> )-amplified residual disease following<br>preoperative anti-HER2 therapy Journal of Clinical Oncology, 2014, 32, 625-625. | 1.6             | 0            |
| 13 | Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC) Journal of Clinical Oncology, 2012, 30, 1017-1017.   | 1.6             | 3            |
| 14 | Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses Journal of Clinical Oncology, 2012, 30, 547-547.   | 1.6             | 1            |